Notably, in tumors such as neuroblastoma, iNKT cells can kill CD1d+ tumor-associated macrophages (TAMs) and convert M2-like suppressive macrophages into pro-inflammatory M1-like macrophages, thereby mitigating TME-mediated immune suppression [114, 123–127]. Here, CD1D is linked to neoplasm.